Viyash Scientific Limited Surges 10% on Strong Earnings Momentum

Viyash Scientific Limited (VIYASH.NS) surged 10.04% to 251.69 INR on the NSE following strong earnings results announced on May 20, 2026. The veterinary healthcare company, formerly known as Sequent Scientific Limited, delivered solid financial performance that sparked investor confidence. Trading volume jumped to 23.2 million shares, significantly above the 867,181 average, signaling robust market participation. This rally reflects growing optimism around the company’s expansion in specialty pharmaceutical formulations for livestock and companion animals across Europe and Asia.

Viyash Scientific Limited Stock Performance and Market Reaction

VIYASH.NS stock trades above its 50-day average of 204.36 and 200-day average of 206.31, confirming upward momentum. The stock hit a day high of 268.70 INR, near its 52-week peak of 268.70 INR, showing strong buying interest. Market capitalization stands at 109.85 billion INR with 436.45 million shares outstanding. The company’s earnings announcement triggered a 22.96 INR jump from the previous close of 228.73 INR, demonstrating market recognition of improved operational performance and financial health in the veterinary pharmaceutical sector.

Financial Metrics and Valuation Analysis

VIYASH.NS trades at a PE ratio of 97.55 with earnings per share of 2.58 INR, reflecting premium valuation typical of growth-stage healthcare companies. The price-to-sales ratio stands at 4.16, while the price-to-book ratio is 3.75, indicating investors value the company’s asset base and future earnings potential. Free cash flow per share reached 0.66 INR, supporting dividend capacity and reinvestment opportunities. The company maintains a healthy current ratio of 2.38, demonstrating strong liquidity to fund operations and expansion initiatives in emerging veterinary markets.

Growth Drivers and Sector Positioning

Revenue grew 13.5% year-over-year, while gross profit surged 33.7%, showcasing operational leverage in the specialty pharmaceutical business. EBIT jumped 15.1%, reflecting improved cost management and pricing power. The Healthcare sector on NSE averages a PE of 41.85, making VIYASH.NS relatively attractive for growth investors. Viyash operates in the Drug Manufacturers – Specialty & Generic industry, providing finished dosage formulations for nutrition, pain management, parasite control, and antibiotics. Track VIYASH.NS on Meyka for real-time updates on this high-growth veterinary healthcare player.

Technical Indicators and Price Momentum

The RSI reading of 72.23 signals overbought conditions, suggesting potential consolidation ahead. The MACD histogram of 2.59 remains positive, supporting continued upside momentum. Volume surged to 23.2 million shares, 26.8 times the average daily volume, confirming institutional buying. The ADX of 29.45 indicates a strong trending market. While technical strength is evident, investors should monitor for profit-taking near resistance levels around 268.70 INR, the current 52-week high.

Final Thoughts

Viyash Scientific Limited’s 10% surge reflects strong earnings execution and growing investor confidence in India’s veterinary healthcare sector. The company’s 13.5% revenue growth and 33.7% gross profit expansion demonstrate operational excellence and market demand for specialty pharmaceutical formulations. With a market cap of 109.85 billion INR and solid cash generation, VIYASH.NS is positioned for sustained growth. However, the elevated PE ratio of 97.55 and overbought technical indicators warrant caution for new entrants. Long-term investors should monitor quarterly results and sector trends closely.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.